Dyax Corp. Highlights Recent Progress In Licensing And Funded Research Portfolio

BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today highlighted recent progress and upcoming milestones in its Licensing and Funded Research Portfolio (LFRP), including, most recently, licensee Eli Lilly and Company’s announcement of the fourth positive Phase 3 study outcome for CYRAMZA™ (ramucirumab). Product candidates in Dyax’s LFRP are eligible for royalties on the first ten years of commercial sales from each antibody program, as well as certain milestone payments. The LFRP currently has 10 product candidates in clinical trials and multiple preclinical programs.

Help employers find you! Check out all the jobs and post your resume.